Alzheimer's disease, amyotrophic lateral sclerosis, or cerebellar ataxia. However, the significance of these endocrine disturbances is not clear. We now report that in two very different inherited neurodegenerative conditions, ataxia-telangiectasia (AT) and Charcot-Marie-Tooth 1A (CMT-1A) disease, serum levels of IGFs are also altered. Both types of patients have increased serum IGF-I and IGFBP-2 levels, and decreased serum IGFBP-1 levels, while only AT patients have high serum insulin levels. Furthermore, serum IGFs are also changed in three different animal models of neurodegeneration: neurotoxin-induced motor discoordination, diabetic neuropathy, and hereditary cerebellar ataxia. In these three models, serum insulin levels are significantly decreased, serum IGF-I and IGFBP-1, -2, and -3 are decreased in diabetic and neurotoxin-injected rats, while serum IGFBP-1 is increased in hereditary ataxic rats. Altogether, these observations indicate that a great variety of neurodegenerative diseases show endocrine perturbations, resulting in changes in serum IGFs levels. These perturbations are disease-specific and are probably due to metabolic and endocrine derangements, nerve cell death, and sickness-related disturbances associated to the neurodegenerative process. Our observations strongly support the need to evaluate serum IGFs in other neurodegenerative conditions.
INTRODUCTION
Recent progress in human genetics have revealed the existence of specific mutations in many types of neurodegenerative diseases (Hardy and GwinnHardy, 1998) . Because the affected proteins are usually widely expressed in the nervous system, the relationship between changes in protein function and appearance of specific patterns of cell death is not yet well understood (Price et al., 1998) . Conceivably, the primary pathogenic effect will lead to death of those cells directly affected by the mutation. Subsequent homeostatic derangements associated to this primary cell death may include a loss of appropriate trophic input to nerve cells not primarily affected by the disease. As a consequence, secondary cell death will proceed. A similar general process is envisaged for nongenetic neurodegenerative processes such as those taking place after isquemic insult, physical injury, or neurotoxin-related neuronal death. Thus, changes in growth factor input, among other pathological alterations, may be an additional factor involved in the progression of neurodegenerative processes. In this regard, we and others previously reported altered levels of
